Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s 2025 Pharmacopoeia Edition Approved, Set for October 1 Implementation

Fineline Cube Mar 26, 2025

The Pharmacopoeia of the People’s Republic of China (2025 Edition), released by the National Medical...

Company

Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab

Fineline Cube Mar 26, 2025

Alphamab Oncology (HKG: 9966) has announced its 2024 financial results, marking a significant milestone with...

Company Drug

Shanghai Henlius Biotech Receives NMPA Approval for HLX79 in Glomerulonephritis Trial

Fineline Cube Mar 26, 2025

China’s Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving approval from the National Medical...

Company Drug

Chia Tai Tianqing’s TQB2210 Approved for Advanced Malignant Tumor Study

Fineline Cube Mar 26, 2025

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved...

Company Deals

CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access

Fineline Cube Mar 26, 2025

China-based CanSino Biologics Inc. (HKG: 6185) has entered into a collaboration agreement with Saudi pharmaceutical...

Company

Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline

Fineline Cube Mar 26, 2025

China-based Everest Medicines (HKG: 1952) has announced its 2024 financial results, marking a significant milestone...

Company Deals

Jiangsu Hengrui Pharmaceuticals Inks Global License Deal with Merck for HRS-5346

Fineline Cube Mar 26, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced a license agreement with US-based giant Merck...

Company Drug

Sichuan Kelun-Biotech Gains NMPA Approval for SKB107 Bone Metastasis Trial

Fineline Cube Mar 26, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving approval from the National...

Company Drug

Abbisko Therapeutics Receives NMPA Approval for ACH Drug ABSK061

Fineline Cube Mar 26, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving clinical trial approval from...

Company Deals

Fapon Biotech Partners with Sansure to Develop Next-Generation Diagnostic Solutions

Fineline Cube Mar 26, 2025

China-based biotech Fapon Biotech Inc. has formed a strategic partnership with molecular diagnostics specialist Sansure...

Company Drug

AstraZeneca Officially Launches Fasenra for Severe Eosinophilic Asthma in China

Fineline Cube Mar 25, 2025

UK-based pharmaceutical giant AstraZeneca Inc. (NASDAQ: AZN) has announced the official market launch of its...

Company Deals Drug

United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug

Fineline Cube Mar 25, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement...

Company Deals

Fapon Biotech Partners with Tencent Healthcare to Boost IVD and Medical Device Fields

Fineline Cube Mar 25, 2025

China-based biotech Fapon Biotech Inc. has formed a strategic partnership with Tencent Healthcare, the healthcare...

Company Drug

Joint Biosciences’ OVV-01 Receives FDA Fast Track Designation for Soft Tissue Sarcoma Trial

Fineline Cube Mar 25, 2025

Shanghai-based Joint Biosciences Ltd., a developer of tumor combined immunotherapies, has announced receiving fast track...

Company Drug

Sino Biopharmaceutical’s Culmerciclib Shows Positive Results in Phase III Breast Cancer Trial

Fineline Cube Mar 25, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has revealed positive results from the Phase III TQB3616-III-02...

Company Drug

Humanwell Healthcare Receives NMPA Approval for Caplyta Generic in Schizophrenia Trial

Fineline Cube Mar 25, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced receiving clinical trial approval from...

Company

Clover Biopharmaceuticals Receives Termination Notice from GAVI for COVID-19 Vaccine Agreement

Fineline Cube Mar 25, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced receiving a one-month prior written notice dated March...

Company

Simcere Pharmaceutical Group Reports Steady Revenue Amid R&D Investment Shift

Fineline Cube Mar 25, 2025

China-based Simcere Pharmaceutical Group (HKG: 2096) has released its 2024 financial performance report, recording RMB...

Company

Henlius Biotech Reports 6.1% Revenue Growth with Strong Oncology Product Sales

Fineline Cube Mar 25, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) has published its 2024 financial results, recording revenues of...

Company

Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals

Fineline Cube Mar 25, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has released its 2024 financial report, recording...

Posts pagination

1 … 212 213 214 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.